204 related articles for article (PubMed ID: 29258618)
1. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Sanborn RE; Ross HJ; Aung S; Acheson A; Moudgil T; Puri S; Hilton T; Fisher B; Coffey T; Paustian C; Neuberger M; Walker E; Hu HM; Urba WJ; Fox BA
J Immunother Cancer; 2017 Dec; 5(1):103. PubMed ID: 29258618
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
3. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
[TBL] [Abstract][Full Text] [Related]
5. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.
Hirschowitz EA; Mullins A; Prajapati D; Baeker T; Kloecker G; Foody T; Damron K; Love C; Yannelli JR
J Thorac Oncol; 2011 Jan; 6(1):169-73. PubMed ID: 21150468
[TBL] [Abstract][Full Text] [Related]
7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
8. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
9. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
10. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.
Perroud MW; Honma HN; Barbeiro AS; Gilli SC; Almeida MT; Vassallo J; Saad ST; Zambon L
J Exp Clin Cancer Res; 2011 Jun; 30(1):65. PubMed ID: 21682877
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
Nemunaitis J; Sterman D; Jablons D; Smith JW; Fox B; Maples P; Hamilton S; Borellini F; Lin A; Morali S; Hege K
J Natl Cancer Inst; 2004 Feb; 96(4):326-31. PubMed ID: 14970281
[TBL] [Abstract][Full Text] [Related]
12. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
Gray JE; Chiappori A; Williams CC; Tanvetyanon T; Haura EB; Creelan BC; Kim J; Boyle TA; Pinder-Schenck M; Khalil F; Altiok S; Devane R; Noyes D; Mediavilla-Varela M; Smilee R; Hopewell EL; Kelley L; Antonia SJ
Cancer Immunol Immunother; 2018 Dec; 67(12):1853-1862. PubMed ID: 30209589
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.
Prell RA; Gearin L; Simmons A; Vanroey M; Jooss K
Cancer Immunol Immunother; 2006 Oct; 55(10):1285-93. PubMed ID: 16408214
[TBL] [Abstract][Full Text] [Related]
14. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K; Sugawara S; Saijo Y; Maemondo M; Sato A; Takamori S; Harada T; Sasada T; Kakuma T; Kishimoto J; Yamada A; Noguchi M; Itoh K; Nakanishi Y
J Immunol Res; 2016; 2016():1745108. PubMed ID: 27274999
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
